Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Sternberg

Showing results (311-320 of 564) with videos related to

Pageof 57
Sort By:
Prostate Cancer and Prostatic Diseases|May 15, 2020
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancerNeal Shore, Celestia S Higano, Daniel J George, et al.
The New England Journal of Medicine|June 28, 2018
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate CancerMaha Hussain, Karim Fizazi, Fred Saad, et al.
The Oncologist|June 17, 2024
TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutationsMark C Markowski, Cora N Sternberg, Hao Wang, et al.
European Urology|April 21, 2018
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision OncologyPhilipp Nuhn, Johann S De Bono, Karim Fizazi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2009
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancerC N Sternberg, H Dumez, H Van Poppel, et al.
ESMO Open|November 17, 2023
Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practiceP Grivas, E Grande, I D Davis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2026
Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With EnzalutamideAndrew J Armstrong, Arun A Azad, Taro Iguchi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2009
Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II studyL Celio, C N Sternberg, R Labianca, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Phase I/II trial of intravesical methotrexate for superficial bladder tumorsC N Sternberg, A Yagoda, N H Bander, et al.
The Journal of Urology|March 1, 1988
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesionH I Scher, A Yagoda, H W Herr, et al.
Pageof 57

Showing results (311-320 of 564) with videos related to

Sort By:
Pageof 57
Prostate Cancer and Prostatic Diseases|May 15, 2020
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancerNeal Shore, Celestia S Higano, Daniel J George, et al.
The New England Journal of Medicine|June 28, 2018
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate CancerMaha Hussain, Karim Fizazi, Fred Saad, et al.
The Oncologist|June 17, 2024
TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutationsMark C Markowski, Cora N Sternberg, Hao Wang, et al.
European Urology|April 21, 2018
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision OncologyPhilipp Nuhn, Johann S De Bono, Karim Fizazi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2009
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancerC N Sternberg, H Dumez, H Van Poppel, et al.
ESMO Open|November 17, 2023
Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practiceP Grivas, E Grande, I D Davis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2026
Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With EnzalutamideAndrew J Armstrong, Arun A Azad, Taro Iguchi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2009
Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II studyL Celio, C N Sternberg, R Labianca, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Phase I/II trial of intravesical methotrexate for superficial bladder tumorsC N Sternberg, A Yagoda, N H Bander, et al.
The Journal of Urology|March 1, 1988
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesionH I Scher, A Yagoda, H W Herr, et al.
Pageof 57